Shares in US biotech Y-mAbs Therapeutics have lost almost a third of their value after FDA advisors unanimously rejected its brain cancer therapy 131I-omburtamab in 16 to 0 vote. The Oncologic Drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results